Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18–inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p =.001) and overall survivals (OS) (p =.0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p =.0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.
Bibliographical noteFunding Information:
The research of Yuval Nov was supported in part by the Israeli Science Foundation grant 286/13.
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
- Acute myeloid leukemia (AML)
- NPM1 mutation
- autologous SCT (ASCT)
- core-binding factor (CBF) translocation
ASJC Scopus subject areas
- Cancer Research